DRGYX | VIVIX | DRGYX / VIVIX | |
Total Expense Ratio | 0.64 | 0.04 | 1,600% |
Annual Report Gross Expense Ratio | 0.64 | 0.04 | 1,600% |
Fund Existence | 12 years | 27 years | - |
Gain YTD | 6.774 | 3.760 | 180% |
Front Load | N/A | N/A | - |
Min. Initial Investment | 1000000 | 5000000 | 20% |
Min. Initial Investment IRA | N/A | N/A | - |
Net Assets | 8.56B | 195B | 4% |
Annual Yield % from dividends | 1.12 | 2.19 | 51% |
Returns for 1 year | 6.11 | 7.30 | 84% |
Returns for 3 years | 19.32 | 27.93 | 69% |
Returns for 5 years | 49.13 | 67.88 | 72% |
Returns for 10 years | 24.99 | 111.08 | 23% |
1 Day | |||
---|---|---|---|
ETFs / NAME | Price $ | Chg $ | Chg % |
UPV | 75.97 | 1.57 | +2.11% |
ProShares Ultra FTSE Europe | |||
FEX | 111.91 | 1.63 | +1.48% |
First Trust Large Cap Core AlphaDEX® ETF | |||
SBIO | 33.15 | 0.46 | +1.39% |
ALPS Medical Breakthroughs ETF | |||
NJAN | 51.57 | 0.46 | +0.89% |
Innovator Growth-100 Pwr Buff ETF™ Jan | |||
QBUF | 28.00 | 0.01 | +0.04% |
Innovator Nasdaq-100 10 Buffr ETF - Qt |